Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 370 participants.
Also called NCT04778787
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 370 participants
- Registry
-
NCT04778787
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT04778787. Randomized; single masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2022-08-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
- Condition
- Congestive Heart Failure
- Intervention (Drug)
- Standard list of drugs used for acute decompensation of CHF (loop diuretics, vasodilators, digoxin, inotropic agents, vasopressors), plus dapagliflozin (Forxiga; MP-002596)
- Lead sponsor
- I.M. Sechenov First Moscow State Medical University
Record details
- Record id
cardio:ct-nct04778787- Content hash
1329ac14371aa2ae308c5596caa0b75a8615258d3418c2066a2b8b515468ebe5